WEBULL
WebtradeDownload

Ambea (OM:AMBEA) Stock Faces Margin Questions Despite EPS Momentum

Simply Wall St · 2d ago

Ambea stock closed at SEK172.3 after the market had a full day to digest the Q2 numbers. The near term share move sits against a very different picture in the financials. Earnings per share for the quarter came in at SEK2.13 and trailing twelve month earnings reached SEK9.55 per share. For a care operator where margins and leverage matter, a trailing net margin of 4.6% and net debt at 2.4 times EBITDA frame the real story investors now need to weigh over the next few years.

Love Ambea’s earnings per share but unsure how comfortable you are with a 4.6% net margin and net debt at 2.4x EBITDA? Compare that setup with companies screened for balance sheet strength and solid fundamentals in our list of solid balance sheet and fundamentals stocks (434 results).

Q2 2026 Earnings Summary

  • Revenue Q2 2026 vs. Q2 2025: SEK 4,419m vs. SEK 4,164m (up 6.1%)
  • Net Income Q2 2026 vs. Q2 2025: SEK 171m vs. SEK 97m (up 76.3%)
  • Basic EPS Q2 2026 vs. Q2 2025: SEK 2.13 vs. SEK 1.15 (up 84.6%)
  • Adjusted EBITDA Margin Q2 2026 vs. Q2 2025: 9.0% vs. 7.5% (improved by 1.5 percentage points)

Prefer clean charts instead of another wall of earnings figures and margin ratios? See Ambea’s full financial picture, with a clear view of its valuation, in the visual company report for Ambea.

OM:AMBEA Trailing 12-Month Earnings & Revenue History as at Aug 2026
OM:AMBEA Trailing 12-Month Earnings & Revenue History as at Aug 2026

Ambea bull case: scale, margins and pipeline under test

Bulls argue that Ambea can use scale, acquisitions and an organic pipeline to lift margins and cash generation while keeping leverage under control. Q2 gives some support. Group revenue grew with 4.4% organic expansion and adjusted EBITDA rose to SEK 397m, with a 9.0% margin and 10.0% on a rolling 12 month view. That aligns with the 9.5% EBITA margin ambition and shows progress in core units like Nytida at roughly 13.2% rolling margin and Vardaga at about 10.0%. Free cash flow of SEK 929m over 12 months and net debt at 2.4x EBITDA indicate the balance sheet is not being stretched by growth or the Finland and Denmark build out. The expanding pipeline of more than 2,200 new care places and planned 480 openings in the next year suggests the volume side of the growth story is on track.

Ambea bear case: leverage, integration and public risk check

Bears worry that Ambea’s acquisition push and public exposure will strain margins and the balance sheet. The current 2.4x net debt to EBITDA is below the 3.25x target, so leverage is not yet at the levels critics fear, although the recommended Humana offer would be an extra test. Integration risk shows up most clearly in Valida and the new Child Welfare segment where short term margin dilution and start up costs are still visible, even if the rolling 12 month margin is around 10.5%. Altiden in Denmark has an EBITDA margin of 3.7% which keeps the turnaround and new legislation benefits firmly in the “work in progress” bucket. Contract hand backs in Vardaga also highlight that public sector relationships can move against the company, even as other municipal partnerships ramp up.

Reveal where the surface looks calm, but the models may quietly diverge from today’s SEK172.3 price by checking the multi year analyst estimates for Ambea.

Stay Ahead With Simply Wall St

If Ambea’s mix of SEK9.55 trailing twelve month EPS, 4.6% net margin and 2.4x net debt to EBITDA has your attention but you are still waiting for the right entry point, register for free with Simply Wall St and add it to your Watchlist to track the share price against fair value estimates in one place. Once you are invested, use the Portfolio Command Center to cut through noise and focus on the key developments that matter for Ambea and your other holdings. For a longer term view, tap into crowd insights and different investment angles through the Community and see how other investors are interpreting the same results. This combination helps you surface potential catalysts and risks early so you can stay ahead of the market rather than reacting to it late.

Seeking Alternatives Beyond Ambea Now

Fresh stock ideas can move from quiet to breakout quickly. Use this momentum while it matters and before they are widely tracked. Do your homework and get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.